Last reviewed · How we verify

NCT04682067: CRUK2

Diabetes Smoking Cessation Incentives Study

Completed NA Last updated 26 May 2022
What this trial tests

NA trial testing Contingency Management in Smoking Cessation in 29 participants. Completed in 7 April 2022.

Timeline
8 January 2021
Primary endpoint
7 April 2022
7 April 2022

Quick facts

Lead sponsorUniversity of Oklahoma
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment29
Start date8 January 2021
Primary completion7 April 2022
Estimated completion7 April 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Oklahoma

Who can join

Adults 18 to 75, any sex, with Smoking Cessation or Diabetes Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the feasibility of contingency management on improving smoking cessation among individuals with type 2 diabetes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Contingency Management

Trials testing the same drug.

Other recruiting trials for Smoking Cessation

Currently open trials in the same condition.

Other University of Oklahoma trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04682067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing